Why Iambic's Nasdaq Filing Will Be Priced on IAM1363, Not Enchant
Iambic Therapeutics filed for a Nasdaq IPO the same morning it announced an AbbVie collaboration. Public markets will still judge the company on whether its brain-penetrant HER2 inhibitor holds up against Enhertu and Tukysa.
San Diego-based Iambic Therapeutics, Inc. filed a Form S-1 on Monday, September 21, 2026, to list on the Nasdaq Global Select Market under the ticker IAM. The initial placeholder size is up to $100 million, with J.P. Morgan, Jefferies, BofA Securities, and Citigroup as joint bookrunners. That figure is a legal stub, not an offering valuation. The company has already raised $461.8 million in private capital from Nvidia, Qatar Investment Authority through Q Healthcare Holding, Catalio Capital Management, Nexus Venture Partners, and Coatue Management.
Founded in 2019 as Entos by CEO Thomas Miller, Ph.D., a former Caltech chemistry professor, and CTO Frederick Manby, Ph.D., a former Bristol professor, Iambic is arriving as a clinical-stage company with 171 full-time employees as of September 18, 2026. Michael Secora, Ph.D., serves as CFO and chief corporate development officer after earlier serving as CFO of Recursion Pharmaceuticals and directing that firm's public market debut. Recursion's subsequent multiple compression, alongside its 2024 acquisition of Exscientia, forms the historical backdrop hanging over this filing. Early AI-biotech market darlings taught public investors to separate platform computational claims from clinical trial outcomes. Iambic is asking the street to examine an AI platform again, but this time anchored to a lead asset already producing clinical responses in patients.
AbbVie Arrived With the S-1, but the P&L Remains a Clinical Burn Story
The same Monday, Iambic and AbbVie announced a multi-year collaboration to discover small-molecule therapies in immunology, neuroscience, and oncology. The work sits on Enchant v3, a multimodal transformer model trained on more than 6,000 molecular properties, and NeuralPLexer. Iambic receives an upfront cash payment and remains eligible for success-based milestones and tiered royalties. AbbVie did not disclose the upfront cash, and the initial S-1 placeholder does not quantify that payment.
The disclosed financial statement details the operational burn. For the six months ended June 30, 2026, collaboration revenue was $12.8 million against an operating loss of $53.5 million and a net loss of $50.1 million. Full-year 2025 collaboration revenue reached $9.4 million, up from $1.2 million in 2024. Trailing twelve-month revenue through June 30, 2026, totaled $18.0 million. While that reflects meaningful biopharma cash inflows, it does not offset late-stage oncology clinical trial expenses. Takeda's discovery pact is worth up to $1.7 billion if bio-milestones materialize. Jazz Pharmaceuticals is combining IAM1363 with zanidatamab (Ziihera) in HER2-positive breast cancer. Bayer, Lundbeck, and Revolution Medicines also populate the partner roster. Upfronts and partner royalties help capitalize the automated robotics loop, but they cannot carry an equity narrative when ten-year Treasury yields hover near 5% and listings from Retention, TRex Bio, and ADARx crowd the autumn window.
The Molecule Public Markets Can Underwrite
IAM1363 is an oral, brain-penetrant, irreversible type II tyrosine kinase inhibitor designed to inhibit wild-type and oncogenic mutant HER2 with more than 5,000-fold selectivity over wild-type EGFR. Iambic advanced the compound from project inception to the clinic in under two years. The Phase 1/1b trial (NCT06253871) in advanced HER2-altered solid tumors has completed dose escalation and is currently enrolling dose-optimization and combination cohorts across the United States, Europe, the United Kingdom, and the Asia-Pacific region.
Initial clinical data represent the core metrics of the roadshow presentation. In heavily pretreated patients dosed at or above 960 mg daily with measurable systemic disease, the confirmed partial response rate was 28% across eighteen evaluable participants. In patients presenting with measurable intracranial brain metastases, the confirmed partial response rate was 33% across three patients. Clinical responses occurred in individuals who previously progressed on antibody-drug conjugates including Enhertu (trastuzumab deruxtecan) and targeted small molecules such as Tukysa (tucatinib). Iambic is planning to initiate a registrational trial as early as 2027, subject to regulatory discussions with the FDA. That intracranial activity represents the central commercial premise, given that central nervous system metastases represent an acute point of therapeutic failure in HER2-driven cancers. However, three patients represent a very small statistical sample, and expanding that cohort remains critical. Competitors already control established lines of therapy, meaning IAM1363 must demonstrate a durable clinical niche in late-line patients rather than simply proving high enzymatic selectivity on biochemical panels.
Two additional internal programs are scheduled for Investigational New Drug applications in the fourth quarter of 2026: IAM217, an allosteric, brain-penetrant KIF18A inhibitor, and IAM-C1, a selective dual CDK2/CDK4 inhibitor. Those filings will broaden pipeline depth during underwriter presentations, but they cannot replace a validated recommended Phase 2 dose, an expanded intracranial patient dataset, and an accepted registrational path for IAM1363.
The Real Trial Begins After the Bell
Iambic's closed-loop design-make-test chemistry laboratories and Enchant v3 architecture successfully drew private venture capital. Public institutional investors will evaluate a far more specific equation: whether a 28% confirmed systemic response rate and early signals in brain metastases can expand in ongoing cohorts, combine safely with zanidatamab, and support a viable registrational design in 2027 after standard-of-care options fail. AbbVie and Takeda validate computational chemistry, but they do not eliminate clinical trial risk. If IAM1363 falters in expansion cohorts, IAM risks trading like previous platform biotechs burdened by heavy operating losses. If intracranial durability deepens, Iambic could offer the clinical proof of concept that earlier AI-driven drug discovery platforms struggled to deliver.